Myasthenia gravis is an autoimmune disorder characterized by fluctuating muscle weakness due to antibodies that block acetylcholine receptors at the neuromuscular junction. It predominantly affects women in their 20s to 30s and men in their 50s to 60s, leading to difficulties in voluntary muscle control, with symptoms varying from eyelid drooping to difficulty swallowing. Management includes pharmacological treatments like acetylcholinesterase inhibitors and immunosuppressants, as well as non-pharmacological strategies, with a prognosis that allows most patients to live normal or nearly normal lives.